CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) – Equities researchers at Jefferies Monetary Group issued their FY2027 earnings per share estimates for CytomX Therapeutics in a report issued on Thursday, January fifth. Jefferies Monetary Group analyst R. Track anticipates that the biotechnology firm will publish earnings of $0.14 per share for the 12 months. The consensus estimate for CytomX Therapeutics’ present full-year earnings is ($1.23) per share.
Different analysts have additionally just lately issued analysis experiences concerning the inventory. BMO Capital Markets raised their worth goal on shares of CytomX Therapeutics from $2.60 to $3.20 and gave the corporate a “market carry out” ranking in a analysis be aware on Friday. JPMorgan Chase & Co. lowered CytomX Therapeutics from an “chubby” ranking to an “underweight” ranking in a analysis be aware on Thursday, November tenth. StockNews.com upgraded shares of CytomX Therapeutics from a “promote” ranking to a “maintain” ranking in a report on Saturday, November nineteenth. Lastly, Wedbush reaffirmed a “impartial” ranking and set a $2.00 worth goal on shares of CytomX Therapeutics in a analysis report on Wednesday, November ninth. One analysis analyst has rated the inventory with a promote ranking, 9 have assigned a maintain ranking and two have assigned a purchase ranking to the corporate’s inventory. Based mostly on knowledge from MarketBeat.com, CytomX Therapeutics has a consensus ranking of “Maintain” and a mean goal worth of $4.91.
CytomX Therapeutics Inventory Efficiency
NASDAQ:CTMX opened at $2.52 on Monday. CytomX Therapeutics has a 1 12 months low of $1.17 and a 1 12 months excessive of $4.73. The inventory has a fifty day transferring common worth of $1.56 and a two-hundred day transferring common worth of $1.54. The inventory has a market capitalization of $166.53 million, a price-to-earnings ratio of -1.69 and a beta of 0.48.
Institutional Inflows and Outflows
Plenty of hedge funds have just lately made adjustments to their positions in CTMX. Clearline Capital LP elevated its place in CytomX Therapeutics by 3.1% throughout the second quarter. Clearline Capital LP now owns 196,583 shares of the biotechnology firm’s inventory value $360,000 after buying a further 5,983 shares throughout the interval. Connor Clark & Lunn Funding Administration Ltd. elevated its holdings in shares of CytomX Therapeutics by 3.4% throughout the second quarter. Connor Clark & Lunn Funding Administration Ltd. now owns 207,071 shares of the biotechnology firm’s inventory value $379,000 after shopping for a further 6,872 shares within the final quarter. Forefront Analytics LLC boosted its holdings in shares of CytomX Therapeutics by 33.3% within the third quarter. Forefront Analytics LLC now owns 47,869 shares of the biotechnology firm’s inventory value $71,000 after buying a further 11,950 shares within the final quarter. Gladius Capital Administration LP purchased a brand new stake in shares of CytomX Therapeutics throughout the second quarter value $25,000. Lastly, Mackenzie Monetary Corp acquired a brand new place in CytomX Therapeutics throughout the 1st quarter value $35,000. Institutional traders and hedge funds personal 70.14% of the corporate’s inventory.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical firm in america. The corporate develops antibody therapeutics based mostly on its Probody expertise platform for the therapy of most cancers. The corporate’s product candidates embody CX-2009, an antibody drug conjugates (ADC) in opposition to CD166, which is in Part II scientific trials for the therapy of breast most cancers; CX-2029 that’s in Part II scientific trials for the therapy of squamous non-small cell lung most cancers, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse massive B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Part I/II scientific trials for the therapy of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Part I scientific trials for the therapy of strong tumors.
This immediate information alert was generated by narrative science expertise and monetary knowledge from MarketBeat with the intention to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you think about CytomX Therapeutics, you will need to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and CytomX Therapeutics wasn’t on the checklist.
Whereas CytomX Therapeutics presently has a “Maintain” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.